GO:0005175 CD27 receptor binding: Mechanism & Genes

CD27 receptor binding (GO:0005175) is a molecular function defined as the selective interaction with CD27, a transmembrane receptor of the TNF receptor superfamily that is primarily expressed on the surface of T cells, some B cells, and NK cells. This binding event is critical for co-stimulatory signaling that shapes adaptive immune responses, including T-cell activation, proliferation, survival, and memory formation. The primary ligand for CD27 is CD70, a type II transmembrane protein of the TNF superfamily, and their interaction triggers receptor trimerization and downstream signaling cascades. Understanding the molecular details of CD27 receptor binding is essential for immunology research and for developing therapeutics that modulate immune responses in cancer, autoimmunity, and infectious diseases. The CD27/CD70 axis has emerged as a promising target in immuno-oncology, with agonistic antibodies and engineered ligands designed to enhance T-cell effector functions. For example, Fc-engineering of anti-CD27 antibodies to optimize clustering and Fcγ receptor engagement has been shown to augment immunostimulation. Additionally, CD70-Fc fusion proteins require Fcγ receptor binding for maximal immunostimulatory activity, underscoring the importance of the binding interface in therapeutic design. Beyond cancer, CD27 receptor binding is implicated in antibody deficiency syndromes and autoimmune conditions, where altered CD27 signaling can disrupt immune homeostasis. Researchers studying CD27 receptor binding utilize a range of experimental models, from gene knockouts and point mutations to knock-in reporters and overexpression systems, to dissect the functional consequences of this interaction. Advanced techniques such as CRISPR library screening and bioinformatics enable systematic interrogation of the CD27 signaling network and identification of novel modulators. This article provides a comprehensive overview of the GO:0005175 term, its mechanistic basis, associated genes, disease relevance, and state-of-the-art research methodologies.

GO:0005175 CD27 receptor binding is a molecular function term that describes the binding to CD27, a receptor found on the surface of T cells and some B cells and NK cells. This function is mediated by ligands such as CD70 and is essential for co-stimulatory signaling in immune cells.

CD27 receptor binding is a pivotal molecular event in adaptive immunity, as it provides co-stimulatory signals that are required for optimal T-cell activation, differentiation into memory cells, and effector functions. Dysregulation of this interaction is associated with immunodeficiencies, autoimmune diseases, and cancer, making it a high-value target for therapeutic intervention. The development of agonistic antibodies and engineered ligands that mimic CD27 receptor binding has opened new avenues in immuno-oncology, particularly for overcoming antigen heterogeneity in malignancies such as acute myeloid leukemia.

The following genes and proteins are central to CD27 receptor binding and its downstream signaling, as supported by published literature.

CD27 receptor binding is regulated at multiple levels, including ligand availability, receptor clustering, and soluble receptor shedding. The expression of CD70 is tightly controlled and transiently induced on activated antigen-presenting cells, limiting the duration of CD27 signaling. Receptor clustering is enhanced by multivalent ligand presentation and can be modulated by Fc-engineering of therapeutic antibodies. Soluble CD27 acts as a decoy to compete for CD70 binding, thereby dampening co-stimulation. Additionally, intracellular signaling is negatively regulated by ubiquitination and degradation of TRAF proteins, which fine-tunes NF-kB activation. Cross-talk with other co-stimulatory pathways, such as CD28 and 4-1BB, further modulates the strength and quality of CD27-mediated signals.

CD27 receptor binding is a key target in cancer immunotherapy due to its ability to enhance T-cell effector functions. Agonistic anti-CD27 antibodies and CD70-Fc fusion proteins are being developed to boost anti-tumor immunity, with Fc-engineering optimizing receptor clustering and Fcγ receptor engagement. In acute myeloid leukemia (AML), CD70 CAR T cells secreting anti-CD33/anti-CD3 dual-targeting antibodies have been shown to overcome antigen heterogeneity, highlighting the therapeutic potential of targeting the CD27/CD70 axis. These strategies rely on precise molecular understanding of CD27 receptor binding to design effective immunotherapeutics.

Dysregulated CD27 receptor binding contributes to antibody deficiency syndromes, including common variable immunodeficiency (CVID). Mutations in TNFRSF13B, which encodes TACI, a related TNF receptor superfamily member, are associated with CVID and can affect CD27 signaling cross-talk. Biallelic versus monoallelic mutations in TNFRSF13B have been distinguished as disease-causing or risk-increasing, underscoring the complexity of TNF receptor superfamily signaling in antibody deficiencies. Understanding CD27 receptor binding in this context may reveal new therapeutic targets for immunodeficiencies.

Altered CD27 receptor binding is implicated in autoimmune diseases, where excessive co-stimulation can lead to tissue damage. Elevated soluble CD27 levels are observed in autoimmune conditions and chronic infections, serving as a biomarker of immune activation. In the context of infectious diseases, CD27 receptor binding is important for vaccine-induced B cell responses, as demonstrated by receptor-binding-domain-specific B cell responses following mRNA immunization against SARS-CoV-2. Additionally, MAIT cell heterogeneity across tissues reveals specialization of distinct regulatory and effector profiles that may depend on CD27 signaling. These findings highlight the broad relevance of CD27 receptor binding in health and disease.

Surface plasmon resonance (SPR) is widely used to measure the binding affinity and kinetics between CD27 and its ligands, such as CD70. This label-free technique provides real-time association and dissociation rates, enabling researchers to quantify the strength of CD27 receptor binding and the impact of mutations or therapeutic antibodies. SPR is particularly valuable for characterizing engineered CD70-Fc variants and anti-CD27 antibodies with modified Fc domains.

Flow cytometry allows the analysis of CD27 surface expression and receptor clustering on T cells, B cells, and NK cells. Using fluorescently labeled antibodies or ligands, researchers can assess the degree of receptor cross-linking and its correlation with downstream signaling. This method is also employed to evaluate the binding of CD70-Fc fusion proteins to CD27-expressing cells and the impact of Fcγ receptor engagement.

CRISPR library screening enables genome-wide identification of genes that regulate CD27 receptor binding and downstream signaling. By knocking out candidate genes in immune cells and assessing CD27-mediated activation, researchers can uncover novel modulators of the pathway. This approach has been used to identify factors that influence the efficacy of CD27-targeted immunotherapies, such as CD70 CAR T cells.

Bioinformatics tools and pathway analysis are essential for interpreting large-scale datasets generated from CD27 receptor binding studies. RNA-seq and proteomics data can be integrated to map the signaling network downstream of CD27, identifying key nodes and potential therapeutic targets. Computational modeling of receptor-ligand interactions further aids in the rational design of CD27 agonists and antagonists.

Researchers studying CD27 receptor binding-related genes often need to determine whether a candidate gene is causally involved in immune regulation or disease. EDITGENE provides comprehensive CRISPR-based services to generate knockout, point-mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics support, enabling precise functional interrogation of the CD27/CD70 axis.

CD27 receptor binding (GO:0005175) is a fundamental molecular function that governs co-stimulatory signaling in T cells, B cells, and NK cells, with critical roles in immune activation, memory formation, and disease. The interaction between CD27 and CD70 has emerged as a promising target for cancer immunotherapy, autoimmune disease modulation, and vaccine development. Advances in CRISPR-based models and bioinformatics are accelerating our understanding of the structural and functional determinants of CD27 receptor binding, paving the way for next-generation immunotherapeutics. As research continues to unravel the complexities of CD27 signaling, precise experimental models and comprehensive analytical tools will be essential. EDITGENE's suite of CRISPR services, from knockout to overexpression and library screening, empowers researchers to interrogate every facet of CD27 receptor binding and translate discoveries into clinical applications.